News

Dr. Reddy’s Laboratories announces the launch of Resof Total in India

Reddy-Laboratories-announces-USFDA-approval

Dr. Reddy’s Laboratories Ltd announced today that it has launched the generic version of Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination, indicated for the treatment of Chronic Hepatitis C, under a brand name Resof Total, in India.

Dr. Reddy’s Resof Total tablets are available in bottle count size of 28.

Reddy-Laboratories-announces-USFDA-approval

Resof Total is used for the treatment of adult patients with Chronic Hepatitis C Virus, Genotype 1,2,3,4,5 or 6 infection

– Without Cirrhosis or with compensated cirrhosis

– With decompensated cirrhosis for use in combination with Ribavirin

The Sofosbuvir 400mg and Velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. Treatment with this combination achieves a cure rate of more than 90% in all genotypes of Hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in Hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of Hepatitis C is upto 70% in Indian patients infected with Hepatitis C.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top